A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer
If you have any questions, please contact:
Deb Lewis
Clinical Research Coordinator
LHSC Victoria Hospital
E2-003
(519) 685-8500 ext 75685
deb.lewis@lhsc.on.ca
